CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Drugmaker Gilead Sciences announced Tuesday that preliminary results from a bioequivalency study of a fixed-dose pill containing its combination anti-HIV drug Truvada with Bristol-Myers Squibb's HIV treatment Sustiva show the first attempt to combine the drugs has failed, TheStreet.com reports. The formulation resulted in levels of Sustiva in the bloodstream below that seen when dosing Sustiva separately, Gilead officials say. Gilead and BMS in December announced an effort to create the first one-pill, once-daily, three-drug HIV treatment by combining Gilead's Truvada--which contains the two separate drugs Viread and Emtriva--and BMS's nonnucleoside reverse transcriptase inhibitor Sustiva. The resulting combination pill would be the simplest triple-drug regimen ever available in the United States. Gilead says it is going to begin a second study with another formulation. The companies, in announcing the joint effort, had said they hoped to have an effective combination pill developed and submitted to the Food and Drug Administration for approval by the end of 2005.
From our Sponsors
Most Popular
Watch Now: Pride Today
Latest Stories
UPenn caves to Trump and bans trans women athletes, stripping Lia Thomas of titles
July 01 2025 5:31 PM
New poll shows who currently leads potential 2028 Democratic presidential field
July 01 2025 4:50 PM
How SNAP cuts will disproportionately impact some LGBTQ+ people
July 01 2025 1:33 PM
Iowa now allows anti-transgender discrimination
July 01 2025 12:11 PM
How a parade invite became a fight for LGBTQ+ visibility in Appalachia
July 01 2025 12:00 PM
10% of new business owners are LGBTQ+ — and they're offering better benefits
July 01 2025 11:20 AM
Catholic school fires Louisiana band director after husband's obituary reveals he is gay
July 01 2025 10:48 AM